Puma Biotechnology Inc reports results for the quarter ended June 30 - Earnings Summary

• Puma Biotechnology Inc PBYI.OQ reported quarterly adjusted earnings of 12 cents​​ per share for the quarter ended June 30, higher than the same quarter last year, when the company reported EPS of -9 cents. The mean expectation of three analysts for the quarter was for earnings of 10 cents per share. Wall Street expected results to range from 10 cents to 11 cents per share.

• Revenue rose 11.3% to $52.40 million from a year ago; analysts expected $50.75 million.

• Puma Biotechnology Inc's reported EPS for the quarter was 12 cents​.

• The company reported quarterly net income of $5.9 million.

• Puma Biotechnology Inc shares had fallen by 5.2% this quarter and gained 6.6% so far this year.

FORECAST CHANGES

• The mean earnings estimate of analysts was unchanged in the last three months.​

• In the last 30 days, there have been no earnings estimate revisions by analysts covering the company.

RECOMMENDATIONS

• The current average analyst rating on the shares is "hold" and the breakdown of recommendations is 1 "strong buy" or "buy," 1 "hold" and 1 "sell" or "strong sell." The average consensus recommendation for the pharmaceuticals peer group is "buy."

• Wall Street's median 12-month price target for Puma Biotechnology Inc is $4.00, about 17.8% above its last closing price of $3.29

This summary was machine generated from LSEG data August 8 at 04:15 a.m. UTC. ​All figures in US dollars unless otherwise stated. (For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com)